Scholarlink

<p> This study aims to assess the safety and effectiveness of transurethral blue laser prostate vaporization (BVP) for elderly patients (≥80 years) with benign prostatic hyperplasia (BPH), focusing on clinical outcomes, recovery, and complications.&#xa0;A retrospective analysis was performed on 157 BPH patients aged ≥ 80 years who underwent BVP at a single center between May 2023 and May 2025. The patients’ general condition was assessed through comorbidities and concurrent surgeries, postoperative outcomes were evaluated through the International Prostate Symptom Score (IPSS), and surgical safety was evaluated based on operative time and postoperative blood tests.&#xa0;The mean age was 83.97 ± 3.63 years, with an average prostate volume of 63.34 ± 34.95&#xa0;ml. Patients had an average of 2.5 comorbidities, and 26.1% required additional surgical interventions. The average procedure time was 28.2 ± 12.1&#xa0;min, with a median hospital stay of 9 days. Postoperative IPSS scores decreased significantly to 4.3 ± 3.5. Mild red blood cell loss (hemoglobin decreased by 6.1%, <i>p</i> &lt; 0.001) and a significant inflammatory response (neutrophils increased by 26.5%, <i>p</i> &lt; 0.001) were observed, but no transfusion was needed.&#xa0;Transurethral blue laser prostate vaporization is a safe and effective option for elderly BPH patients with multiple comorbidities, offering significant symptom improvement with minimal postoperative complications.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Application of transurethral blue laser vaporization of the prostate in patients aged 80 and above: a single-center clinical analysis of 157 cases

  • 期刊论文

  • 发表日期：

    2025年12月20日

查看全文
  • Chao Wang,
  • Xiaoliang Fu,
  • Yayun Ji,
  • Haifeng Cheng,
  • Sizhen Wang,
  • Guoxiong Liu,
  • Zhenwei Fan,
  • Jianing Qiao,
  • Xiaofeng Xu,
  • Quan Du

摘要

This study aims to assess the safety and effectiveness of transurethral blue laser prostate vaporization (BVP) for elderly patients (≥80 years) with benign prostatic hyperplasia (BPH), focusing on clinical outcomes, recovery, and complications. A retrospective analysis was performed on 157 BPH patients aged ≥ 80 years who underwent BVP at a single center between May 2023 and May 2025. The patients’ general condition was assessed through comorbidities and concurrent surgeries, postoperative outcomes were evaluated through the International Prostate Symptom Score (IPSS), and surgical safety was evaluated based on operative time and postoperative blood tests. The mean age was 83.97 ± 3.63 years, with an average prostate volume of 63.34 ± 34.95 ml. Patients had an average of 2.5 comorbidities, and 26.1% required additional surgical interventions. The average procedure time was 28.2 ± 12.1 min, with a median hospital stay of 9 days. Postoperative IPSS scores decreased significantly to 4.3 ± 3.5. Mild red blood cell loss (hemoglobin decreased by 6.1%, p < 0.001) and a significant inflammatory response (neutrophils increased by 26.5%, p < 0.001) were observed, but no transfusion was needed. Transurethral blue laser prostate vaporization is a safe and effective option for elderly BPH patients with multiple comorbidities, offering significant symptom improvement with minimal postoperative complications.